AZN · Astrazeneca PLC
Market Cap
$257.87B
Shares
1.55B
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$58.74B
+8.6%
FY2025
Net Income
$10.23B
+45.3%
FY2025
Gross Margin
81.9%
+0.8pp
FY2025
Operating Margin
23.4%
+4.9pp
FY2025
Diluted EPS
$6.54
+45.3%
FY2025
Operating Cash Flow
$14.58B
+22.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $58.74B | $54.07B | $45.81B | $44.35B | $37.42B | $26.62B | $24.38B | $22.09B | $22.47B | $23B | $24.71B | |
| $10.63B | $10.21B | $8.27B | $12.39B | $12.44B | $5.3B | $4.92B | $4.94B | $4.32B | $4.13B | $4.65B | |
| $48.11B | $43.87B | $37.54B | $31.96B | $24.98B | $21.32B | $19.46B | $17.15B | $18.15B | $18.88B | $20.06B | |
| 81.9% | 81.12% | 81.95% | 72.06% | 66.76% | 80.09% | 79.82% | 77.66% | 80.78% | 82.06% | 81.2% | |
| $14.23B | $13.58B | $10.94B | $9.76B | $9.74B | $5.99B | $6.06B | $5.93B | $5.76B | $5.89B | $6B | |
| $579M | $555M | $539M | $536M | $446M | $399M | $339M | $331M | $310M | $326M | $339M | |
| $13.74B | $10B | $8.19B | $3.76B | $1.06B | $5.16B | $2.92B | $3.39B | $3.68B | $4.9B | $4.11B | |
| 23.4% | 18.5% | 17.88% | 8.47% | 2.82% | 19.39% | 11.99% | 15.33% | 16.37% | 21.31% | 16.65% | |
| $1.69B | $1.74B | $1.63B | $1.35B | $1.3B | $1.31B | $1.43B | $1.42B | $1.51B | $1.38B | $1.08B | |
| $2.17B | $1.65B | $938M | -$792M | -$380M | $772M | $321M | -$57M | -$641M | $146M | $243M | |
| $10.23B | $7.04B | $5.96B | $3.29B | $115M | $3.14B | $1.23B | $2.05B | $2.87B | $3.41B | $2.83B | |
| 17.42% | 13.02% | 13.01% | 7.42% | 0.31% | 11.81% | 5.03% | 9.28% | 12.77% | 14.81% | 11.44% | |
| USD/shares | $6.60 | $4.54 | $3.84 | $4.24 | $0.16 | $4.88 | $2.06 | $3.40 | $4.74 | $5.54 | $4.46 |
| USD/shares | $6.54 | $4.50 | $3.81 | $4.22 | $0.16 | $4.88 | $2.06 | $3.40 | $4.74 | $5.52 | $4.46 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2015–FY2025: $751M in buybacks, $43.52B in dividends.